RT Journal Article
SR Electronic
T1 Study Protocol of A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localized Rectal Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.31.21265647
DO 10.1101/2021.10.31.21265647
A1 Corrò, Claudia
A1 Buchs, Nicolas C.
A1 Tihy, Matthieu
A1 Durham-Faivre, André
A1 Bichard, Philippe
A1 Frossard, Jean-Louis
A1 Puppa, Giacomo
A1 McKee, Thomas
A1 Roth, Arnaud
A1 Zilli, Thomas
A1 Trembleau, Christelle
A1 Marco, Mariagrazia Di
A1 Dutoit, Valérie
A1 Dietrich, Pierre-Yves
A1 Ris, Frédéric
A1 Kössler, Thibaud
YR 2021
UL http://medrxiv.org/content/early/2021/11/01/2021.10.31.21265647.abstract
AB Background Reshaping the tumor microenvironment by novel immunotherapies represents a key strategy to improve the treatment of cancers. Nevertheless, responsiveness to these treatments is often correlated with the extent of the T cell infiltration at the tumor site. Remarkably, microsatellite stable rectal cancer is characterized by poor infiltration and, therefore, do not respond to immune checkpoint blockade. To date, the only available curative option for these patients relies on extensive surgery. With the aim to broaden the application of promising immunotherapies, it is necessary to develop alternative approaches to promote T cell infiltration into the tumor microenvironment of these tumors. In this regard, recent evidence shows that radiotherapy may have profound immunostimulatory effects, hinting at the possibility of combining it with immunotherapy. The combination of long-course chemoradiotherapy and immunotherapy was recently shown to be safe and yielded promising results in rectal cancer, however short-course radiotherapy and immunotherapy have never been tested in these tumors.Methods Our clinical trial investigates the clinical and biological impact of combining pembrolizumab with short-course radiotherapy in the neo-adjuvant treatment of localized microsatellite stable rectal cancer. This phase II non-randomized study will recruit 25 patients who will receive short-course preoperative radiotherapy (5Gy x 5 days) and four injections of pembrolizumab starting on the same day and on weeks 4, 7 and 10. Radical surgery will be performed after three weeks from the last pembrolizumab injection. Our clinical trial also includes an extensive research program involving the transcriptomic and proteomic analysis of blood and tumor samples throughout the course of the treatment.Discussion Our study is the first clinical trial to provide with safety and efficacy information of this novel treatment approach in rectal cancer, leading to a major breakthrough in the treatment of this cancer. Additionally, the translational research program will offer better insight into immunological changes within the tumor and blood during treatment. Taken together, our work will help optimizing future treatment combinations and, possibly, better selecting patients.Trial registration This study was registered with www.clinicaltrial.gov: NCT04109755. Registration date: June, 2020.Competing Interest StatementTK discloses consulting or advisory role for MSD, BMS, Lilly, Roche, Boeringer Ingelheim and Servier. TZ declares the following conflict of interests. Honoraria/Travel costs (institutional): Janssen, Amgen, Ferring, Debiopharm, Bayer, Astellas; Research Grants (institutional): Varian Medical Systems, Debiopharm; Advisory Boards (institutional): Janssen. All other authors declare that they have no competing interests.Clinical TrialNCT04109755Funding StatementThe study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This clinical study (registration number: NCT04109755) has received ethical approval from the Regional Research and Ethics Committee (CCER) and Swissethics (Protocol number: 2018-02346). A written informed consent is obtained from all participants upon participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.CRTChemoradiotherapyCTChemotherapyctDNACirculating tumor DNACTComputed tomographyCTLA-4Cytotoxic T lymphocyte-associated protein 4dMMRDeficient mismatch repair mechanismsDMFSDistant metastasis-free survivalECOGEastern co-operative oncology groupEUSEndoscopy ultrasoundICIImmune checkpoint inhibitorIVIntravenouslyLRRFSLocoregional relapse-free survivalMRIMagnetic resonance imagingMSIMicrosatellite instabilityMSSMicrosatellite stableOSOverall survivalPBMCPeripheral blood mononuclear cellPTVPlanning target volumePD1Programmed cell death 1PD-L1Programmed cell death ligand 1PFSProgression free survivalRTRadiotherapyRCRectal CancerTregsRegulatory T cellsSCPRTShort-course preoperative radiotherapyTMETumor microenvironmentTRGTumor regression gradeTILTumor-infiltrating lymphocyteVMATVolumetric-modulated arc therapy